Florida Senate
-
2025
(Proposed Bill) SPBSB 7028
FOR CONSIDERATION By
By
the Committee on Health Policy
588-02667A-25 20257028pb588-02849-25 20257028__
1 A bill to be entitled
251 párrafos sin cambios
2 An act relating to cancer; amending s. 381.915, F.S.;
3 revising the definitions of the terms “cancer center”
4 and “Florida-based”; defining the term “Cancer Connect
5 Collaborative” or “collaborative”; making clarifying
6 changes; deleting an obsolete date; revising the
7 composition of the collaborative; deleting obsolete
8 provisions; requiring the collaborative to review all
9 submitted Cancer Innovation Fund grant applications
10 using certain parameters; requiring the collaborative
11 to give priority to certain applications; requiring
12 licensed or certified health care providers,
13 facilities, or entities to meet certain criteria to be
14 eligible for specified grant funding; specifying such
15 criteria; requiring the Department of Health to
16 appoint peer review panels for a specified purpose;
17 requiring that priority scores be forwarded to the
18 collaborative and be considered in determining which
19 proposals the collaborative recommends for certain
20 grant funding; requiring the collaborative and peer
21 review panels to establish and follow certain
22 guidelines and adhere to a certain policy; prohibiting
23 a member of the collaborative or a panel from
24 participating in certain discussions or decisions
25 under certain circumstances; requiring, beginning on a
26 specified date and annually thereafter, the
27 collaborative to prepare and submit a specified report
28 to the Governor and the Legislature; requiring that
29 the report include certain information; revising the
30 requirements for a specified report by the department;
31 requiring, beginning on a specified date, that certain
32 allocation agreements include certain information;
33 providing legislative findings; creating the Cancer
34 Connect Collaborative Research Incubator within the
35 department, and overseen by the collaborative, to
36 provide funding for a specified purpose over a
37 specified timeframe; specifying the incubator’s
38 targeted area of cancer research for the first
39 specified timeframe; providing that grants issued
40 through the incubator are contingent upon the
41 appropriation of funds and must be awarded through a
42 specified process; requiring that priority be given to
43 certain applicants; authorizing the prioritization of
44 certain grant proposals; providing that applications
45 for incubator funding may be submitted by specified
46 hospitals; requiring that all qualified applicants
47 have equal access and opportunity to compete for
48 research funding; requiring that incubator grants be
49 recommended by the collaborative and awarded by the
50 department in a certain manner; requiring the
51 department to appoint peer review panels for a
52 specified purpose; requiring that priority scores be
53 forwarded to the collaborative and be considered in
54 determining which proposals the collaborative
55 recommends for funding; requiring the collaborative
56 and peer review panels to establish and follow certain
57 guidelines and adhere to a certain policy; prohibiting
58 a member of the collaborative or a panel from
59 participating in certain discussions or decisions;
60 requiring recipients of incubator grant funds to enter
61 into an allocation agreement with the department;
62 specifying requirements for such allocation
63 agreements; requiring, beginning on a specified date
64 and annually until a specified date, the collaborative
65 to prepare and submit a specified report to the
66 Governor and the Legislature; requiring the
67 collaborative to make a certain recommendation under
68 certain circumstances; requiring that a specified
69 report include certain information; amending s.
70 381.922, F.S.; establishing the Bascom Palmer Eye
71 Institute VisionGen Initiative within the William G.
72 “Bill” Bankhead, Jr., and David Coley Cancer Research
73 Program; providing the purpose of the initiative;
74 providing that funding for the initiative is subject
75 to annual appropriation; providing an effective date.
76
77 Be It Enacted by the Legislature of the State of Florida:
78
79 Section 1. Present paragraphs (c), (d), and (e) of
80 subsection (3) and present subsections (12) and (13) of section
81 381.915, Florida Statutes, are redesignated as paragraphs (d),
82 (e), and (f) of subsection (3) and subsections (13) and (14),
83 respectively, a new paragraph (c) is added to subsection (3),
84 paragraph (d) is added to subsection (10), a new subsection (12)
85 is added to that section, and paragraph (b) and present
86 paragraph (c) of subsection (3), paragraphs (a), (b), (e), (f),
87 and (h) of subsection (8), and subsections (9) and (11) of that
88 section are amended, to read:
89 381.915 Casey DeSantis Cancer Research Program.—
90 (3) On or before September 15 of each year, the department
91 shall calculate an allocation fraction to be used for
92 distributing funds to participating cancer centers. On or before
93 the final business day of each quarter of the state fiscal year,
94 the department shall distribute to each participating cancer
95 center one-fourth of that cancer center’s annual allocation
96 calculated under subsection (6). The allocation fraction for
97 each participating cancer center is based on the cancer center’s
98 tier-designated weight under subsection (4) multiplied by each
99 of the following allocation factors based on activities in this
100 state: number of reportable cases, peer-review costs, and
101 biomedical education and training. As used in this section, the
102 term:
103 (b) “Cancer center” means a comprehensive center with at
104 least one geographic site in the state, a freestanding center
105 located in the state, a center situated within an academic
106 institution, or a Florida-based formal research-based consortium
107 under centralized leadership that has achieved NCI designation
108
or is prepared to achieve NCI designation by June 30, 2024
.
109
(c) “Cancer Connect Collaborative
” or “collaborative
” means
110
the council created under s
ubs
ection (8).
111
(d)
(c)
“Florida-based” means that a cancer center’s actual
112 or sought designated status is or would be recognized by the NCI
113 as primarily located in Florida and not in another state
, or
114
that a health care provider or facility is physically located in
115
Florida and provides services in Florida
.
116 (8) The Cancer Connect Collaborative, a council as defined
117 in s. 20.03, is created within the department to advise the
118 department and the Legislature on developing a holistic approach
119 to the state’s efforts to fund cancer research, cancer
120 facilities, and treatments for cancer patients. The
121 collaborative may make recommendations on proposed legislation,
122 proposed rules, best practices, data collection and reporting,
123 issuance of grant funds, and other proposals for state policy
124 relating to cancer research or treatment.
125 (a) The Surgeon General shall serve as an ex officio,
126 nonvoting member
of the collaborative
and shall serve as the
127 chair.
128 (b) The collaborative shall be composed of the following
129 voting members
, to be appointed by September 1, 2024
:
130 1. Two members appointed by the Governor,
t
hree
members
one
131
member
appointed by the President of the Senate, and
t
hree
132
members
one member
appointed by the Speaker of the House of
133 Representatives, based on the criteria of this subparagraph. The
134 appointing officers shall make their appointments prioritizing
135 members who have the following experience or expertise:
136 a. The practice of a health care profession specializing in
137 oncology clinical care or research;
138 b. The development of preventive and therapeutic treatments
139 to control cancer;
140 c. The development of innovative research into the causes
141 of cancer, the development of effective treatments for persons
142 with cancer, or cures for cancer; or
143 d. Management-level experience with a cancer center
144 licensed under chapter 395.
145 2. One member who is a resident of this state who can
146 represent the interests of cancer patients in this state,
147 appointed by the Governor.
148 (e) Members
of the collaborative
whose terms have expired
149 may continue to serve until replaced or reappointed, but for no
150 more than 6 months after the expiration of their terms.
151 (f) Members
of the collaborative
shall serve without
152 compensation but are entitled to reimbursement for per diem and
153 travel expenses pursuant to s. 112.061.
154
(h)
The collaborative shall develop a long-range
155
comprehensive plan for the Casey DeSantis Cancer Research
156
Program. In the development of the plan, the collaborative must
157
solicit input from cancer centers, research institutions,
158
biomedical education institutions, hospitals, and medical
159
providers. The collaborative shall submit the plan to the
160
Governor, the President of the Senate, and the Speaker of the
161
House of Representatives no later than December 1, 2024. The
162
plan must include, but need not be limited to, all of the
163
following components:
164
1. Expansion of grant fund opportunities to include a
165
broader pool of Florida-based cancer centers, research
166
institutions, biomedical education institutions, hospitals, and
167
medical providers to receive funding through the Cancer
168
Innovation Fund.
169
2. An evaluation to determine metrics that focus on patient
170
outcomes, quality of care, and efficacy of treatment.
171
3. A compilation of best practices relating to cancer
172
research or treatment
.
173 (9)
(a)
The collaborative shall advise the department on the
174 awarding of grants issued through the Cancer Innovation Fund.
175 During any fiscal year for which funds are appropriated to the
176 fund, the collaborative shall review all submitted grant
177 applications
using the parameters provided in
paragraph (
c
)
and
178 make recommendations to the department for awarding grants to
179 support innovative cancer research and treatment models,
180 including emerging research and treatment trends and promising
181 treatments that may serve as catalysts for further research and
182 treatments. The department shall make the final grant allocation
183 awards. The collaborative shall give priority to applications
184 seeking to expand the reach of
cancer screening efforts and
185 innovative cancer treatment models into underserved areas of
186 this state.
187
(
b
)
To be eligible for grant funding under this sectionsubsection, a
188
a
licensed or certified health care provider, facility, or entity
189
entity
must
631 párrafos sin cambios
meet
at least one of
the following criteria
:
190
1
. Operate
s
as
a licensed hospital that has a minimum of 30
191
percent
of
its
current cancer patients
residing
in rural or
192
underserved areas
.
193
2
. Operate
s
as
a licensed health care clinic or facility
194
that employs or contracts with at least one physician
licensed
195
under chapter 458 or chapter 459
who
is board certified
in
196
oncology and that
administers
chemotherapy treatments for
197
cancer
.
198
3
. Operate
s
as
a licensed facility that employs or
199
contracts with at least one
physician licensed under chapter 458
200
or chapter 459 who is board
certified in oncology
and that
201
administers
radiation therapy treatments for cancer
.
202
4.
Operate
s
as
a licensed health care clinic or facility
203
that provides cancer screening services at no cost or a minimal
204
cost to patients.
205
5
. Operate
s
as a rural hospital as defined in s.
206
395.602(2)(b)
.
207
6
. Operate
s
as a critical access hospital as defined in s.
208
408.07(14)
.
209
7
. Operate
s
as a specialty hospital as defined in s.
210
395.002(28)(a)
which
provides cancer treatment for
patients
from
211
birth to
18 years
of age.
212
8
. Engage
s
in biomedical research intended to develop
213
therapies, medical pharmaceuticals, treatment protocols, or
214
medical procedures intended to cure cancer or improve the
215
quality of life of cancer patients
.
216
9
. Educate
s
or train
s
students, postdoctoral fellows, or
217
licensed or certified health care practitioners in the
218
screening, diagnosis, or treatment of cancer.
219
(
c
) To ensure that all proposals for
grant funding
issued
220
through the Cancer Innovation Fund are appropriate and are
221
evaluated fairly on the basis of scientific merit, the
222
department shall appoint peer review panels of independent,
223
scientifically qualified individuals to review the scientific
224
merit of each proposal and establish its priority score. The
225
priority scores
must
be forwarded to the collaborative and must
226
be considered in determining which proposals the collaborative
227
recommends
for grant funding through the
Cancer Innovation Fund.
228
(
d
) The collaborative and the peer review panels shall
229
establish and follow rigorous guidelines for ethical conduct and
230
adhere to a strict policy with regard to conflicts of interest
231
regarding the assessment of Cancer Innovation Fund grant
232
applications. A member of the collaborative or a panel may not
233
participate in any discussion or decision of the collaborative
234
or a panel with respect to a research proposal by any firm,
235
entity, or agency with which the member is associated as a
236
member of the governing body or as an employee or with which the
237
member has entered into a contractual arrangement.
238
(
e
)
Beginning December 1, 2025, and annually thereafter,
239
t
he collaborative shall
prepare and submit
a report to the
240
Governor,
the
President of the Senate, and
the
Speaker of the
241
House of Representative
s
which
identifies and evaluates
the
242
performance and
the impact
of
grants issued through
the
Cancer
243
Innovation Fund
on cancer treatment,
research,
screening,
244
diagnosis, prevention, practitioner
training,
workforce
245
education, and
cancer patient
survivorship. The report
must
246
include
all of
the following:
247
1
. Amounts of grant funds awarded to each
recipient
.
248
2
. Descriptions of each
recipien
t’s research or project
249
which
include
, but need not be limited to,
the following:
250
a.
Goals or projected outcomes
.
251
b.
Population to be served
.
252
c.
Research methods or project implementation plan
.
253
3
.
An assessment of
grant recipients
which
evaluates
their
254
p
rogress
toward achieving objectives specified in
each
255
recipient’s
grant application.
256
4
.
Recommendations for best practices
that may
be
257
implemented by health care providers in
this state
who
diagnose,
258
treat, and screen for cancer
, based on the outcomes of projects
259
funded through the Cancer Innovation Fund
.
260 (10) Beginning July 1, 2025, and each year thereafter, the
261 department, in conjunction with participating cancer centers,
262 shall submit a report to the Cancer Control and Research
263 Advisory Council and the collaborative on specific metrics
264 relating to cancer mortality and external funding for cancer
265 related research in this state. If a cancer center does not
266 endorse this report or produce an equivalent independent report,
267 the cancer center is ineligible to receive program funding for 1
268 year. The department must submit this annual report, and any
269 equivalent independent reports, to the Governor, the President
270 of the Senate, and the Speaker of the House of Representatives
271 no later than September 15 of each year the report or reports
272 are submitted by the department. The report must include:
273
(d) A description of the numbers and types of cancer cases
274
treated
annually at each participating cancer center
, including
275
reportable and nonreportable cases
.
276 (11) Beginning July 1,
2025
2024
, each allocation agreement
277 issued by the department relating to cancer center payments
278 under
paragraph (2)(a)
subsection (2)
must include all of the
279 following:
280 (a) A line-item budget narrative documenting the annual
281 allocation of funds to a cancer center.
282 (b) A cap on the annual award of 15 percent for
283 administrative expenses.
284 (c) A requirement for the cancer center to submit quarterly
285 reports of all expenditures made by the cancer center with funds
286 received through the Casey DeSantis Cancer Research Program.
287 (d) A provision to allow the department and other state
288 auditing bodies to audit all financial records, supporting
289 documents, statistical records, and any other documents
290 pertinent to the allocation agreement.
291 (e) A provision requiring the annual reporting of outcome
292 data and protocols used in achieving those outcomes.
293
(12)(a)
The Legislature finds that targeted areas of cancer
294
research require increased resources and that Florida should
295
become a leader in promoting research opportunities for these
296
targeted areas. Floridians should not have to leave the state to
297
receive the most advanced cancer care and treatment. To meet
298
this need, the Cancer Connect Collaborative Research Incubator
,
299
or “incubator” as used in this subsection,
is created within the
300
department, to be overseen by the collaborative, to provide
301
funding for a targeted area of cancer research
over
a
5
-year
302
period. For the
5
-year period beginning July 1, 2025, the
303
i
ncubator’s targeted area of cancer research
is
pediatric
304
cancer.
305
(b)
Contingent
up
on the appropriation of funds by the
306
Legislature, grants issued through the
i
ncubator
must
be awarded
307
through a peer-reviewed, competitive process.
Priority
must
be
308
given to applicants that focus on
enhancing
both research and
309
treatment
by increasing
participation in clinical trials
related
310
to the targeted area of cancer research, including
all of the
311
following
:
312
1. Identifying
strategies
to increase enrollment in cancer
313
clinical trials
.
314
2. Supporting public and private professional education
315
programs
to raise
awareness and knowledge about cancer clinical
316
trials
.
317
3. Providing tools
for
cancer patients and community-based
318
oncologists to
help identify available cancer clinical trials i
n
319
th
is
state
.
320
4. Creating opportunities for the state’s academic cancer
321
centers to collaborate with community-based oncologists in
322
cancer clinical trial
networks.
323
(c)
Priority
may be given to grant proposals that foster
324
collaborations among institutions, researchers, and community
325
practitioners to support the advancement of cures through basic
326
or applied research, including clinical trials involving cancer
327
patients and related networks.
328
(d) Applications for
i
ncubator funding may be submitted by
329
any Florida-based specialty hospital as defined in s.
330
395.002(28)(a)
which
provides cancer treatment for patients from
331
birth to 18 years
of age
. All qualified applicants
must
have
332
equal access and opportunity to compete for research funding.
333
Incubator grants
must
be recommended by the collaborative and
334
awarded by the department on the basis of scientific merit, as
335
determined by a competitively open and peer-reviewed process to
336
ensure objectivity, consistency, and high quality.
337
(e) To ensure that all proposals for research funding are
338
appropriate and are evaluated fairly on the basis of scientific
339
merit, the department shall appoint peer review panels of
340
independent, scientifically qualified individuals to review the
341
scientific merit of each proposal and establish its priority
342
score. The priority scores
must
be forwarded to the
343
collaborative and must be considered in determining which
344
proposals the collaborative recommends for funding.
345
(f) The collaborative and the peer review panels shall
346
establish and follow rigorous guidelines for ethical conduct and
347
adhere to a strict policy with regard to conflicts of interest
348
regarding the assessment of incubator grant applications
. A
349
member of the collaborative or a panel may not participate in
350
any discussion or decision of the collaborative or a panel
351
regarding
a research proposal
from
any firm, entity, or agency
352
with which the member is associated
as a governing body member,
353
as an employee, or through
a contractual arrangement.
354
(g) Each recipient of
i
ncubator grant funds must enter into
355
an allocation agreement with the department. Each such
356
allocation agreement must include all of the following:
357
1. A line-item budget narrative documenting the annual
358
allocation of funds to a recipient.
359
2. A cap on the annual award of 15 percent for
360
administrative expenses.
361
3. A requirement for the recipient to submit quarterly
362
reports of all expenditures made by the recipient with funds
363
received through the
incubator.
364
4. A provision to allow the department and other state
365
auditing bodies to audit all financial records, supporting
366
documents, statistical records, and any other documents
367
pertinent to the allocation agreement.
368
5. A provision requiring the annual reporting of outcome
369
data and protocols used in achieving those outcomes.
370
(h) Beginning December 1, 2026, and annually through
371
December 1, 2030, the collaborative shall
prepare and
submit a
372
report to the Governor,
the
President of the Senate, and
the
373
Speaker of the House of Representatives
which
evaluates research
374
conducted through the
i
ncubator and provides details on outcomes
375
and findings available through the end of the fiscal year
376
immediately preceding each report. If the collaborative
377
recommend
s
that the
i
ncubator be extended beyond its
5
-year
378
lifespan, the collaborative shall make such recommendation in
379
the report due December 1, 2029, and shall include a
380
recommendation for the next targeted area of cancer research.
381
The report due on December 1, 2030, must include
all of the
382
following
:
383
1.
Details of all results of the research conducted with
384
i
ncubator funding
which
has been completed or the status of
385
research in progress.
386
2.
An evaluation of all research conducted with
i
ncubator
387
funding during the
5
fiscal years preceding the report.
388 Section 2. Paragraph (d) is added to subsection (2) of
389 section 381.922, Florida Statutes, to read:
390 381.922 William G. “Bill” Bankhead, Jr., and David Coley
391 Cancer Research Program.—
392 (2) The program shall provide grants for cancer research to
393 further the search for cures for cancer.
394
(d) There is established within the program the
Bascom
395
Palmer Eye Institute
VisionGen
Initiative. The purpose of the
396
initiative is to advance
genetic and epigenetic research on
397
inherited eye diseases and ocular oncology
by awarding grants
398
through the peer-reviewed, competitive process established under
399
subsection (3).
Funding for the initiative
is subject to the
400
annual appropriation of funds by the Legislature.
401 Section 3. This act shall take effect July 1, 2025.